Sponsors
Bring Predictability Back to Enrollment.
Every day of delay costs millions. Polus Health eliminates enrollment waste, accelerates First candidate In, and delivers predictable, audit-ready trials. Your therapies will reach candidates faster, at a lower cost, and with stronger regulator confidence.
The Problem
Enrollment is Moving, But It’s Becoming Harder to Predict.
Your study is active, sites are engaged, and recruitment is underway, but over time a pattern begins to emerge:
- A few sites begin to lag
- Screen failures rise across key locations
- Forecasts become increasingly difficult to defend
What initially appears manageable begins to compound as variability builds across your site network, slowing enrollment, extending timelines, and eroding confidence in your projections.
The Real Bottleneck
The Problem Isn’t Recruitment. It’s Variability.
You may track average screen failure across your study, but variability across your sites is what ultimately breaks your enrollment forecasts. When unqualified candidates enter screening, performance becomes inconsistent from one site to the next.
By the time that variance becomes visible, recovery usually means adding sites, increasing budget, or accepting delay.
A New Way Forward
Start with Candidates Who Are Already Qualified.
Polus Health validates eligibility before candidates ever reach your sites so your study starts with candidates who are ready.
- Reduce screen-failures by 50%
- Cut enrollment timelines by 30-60 days
- Eliminate enrollment variance
You don’t change how sites operate. You improve what enters their workflow.
How It Works
From Prescreening to Qualified-Candidate
Step 1: Structured Intake
Your protocol, inclusion and exclusion criteria, and imaging requirements are structured into a prescreening layer tailored to your study.
candidate data and imaging are evaluated early to identify candidates who align with your protocol before screening begins.
This creates a more consistent and traceable intake process across your sites, reducing variability at the earliest stage.
Step 2: Upstream Validation
Each candidate is reviewed and confirmed prior to site contact using a combination of AI models and certified coordinators and retinal specialists.
This includes evaluation of OCT, FA, and fundus photography (FP) imaging, along with EMR data, against protocol criteria to ensure eligibility is accurate before screening begins.
This is not a first-pass filter. It is a clinical validation step that ensures consistent application of your protocol and reduces screen failures across your sites.
Step 3: Clean Handoff
Sites receive a clear, documented report of pre-validated candidates aligned to your protocol and regulatory expectations.
This results in predictable enrollment curves, enrollment-ready screening documentation, and higher confidence in feasibility projections across your portfolio.
Why Polus Health
What Changes When Enrollment Becomes Predictable
Fewer Screen-Fails
Reduce screen failures by up to 50%, with performance aligned to an outcomes-based model that incentivizes early eligibility validation.
Stronger Site Performance
Identify top-enrolling sites earlier by improving the quality of candidates entering each site’s workflow.
Improved Protocol Compliance
Ensure more consistent application of protocol criteria across sites through structured intake and clinical validation.
Faster Enrollment Completion
Accelerate Last Patient In (LPI) by reducing screening inefficiencies that slow enrollment over time.
Faster Path to Approval
Enable more efficient data collection and reporting, supporting faster regulatory timelines and FDA submission readiness.
See How Your Enrollment Can Be Improved
Who We Are
Built by Retina Trial Veterans. Designed for Timeline Reliability.
Our team has led, supported, and executed retina trials for decades. We understand protocol complexity, imaging nuance, and the operational pressure behind every milestone. That’s why Polus was built: to give sponsors and CROs a scalable, scientifically rigorous enrollment engine they can rely on.
We bring clinical expertise, AI-supported validation, and standardized prescreening together to eliminate variability before it becomes delay.
The result: faster enrollment, fewer failed screens, and the confidence that every patient entering your funnel truly meets the protocol.
Therapeutic Areas
Expertise in the Trials You Are Running
Our team has worked across the same retina and imaging-driven trials you are running and supports them with deep expertise in protocol criteria, imaging, and eligibility logic.
Diabetic Macular Edema (DME)
Diabetic Retinopathy (DR)
- Proliferative Diabetic
- Retinopathy (PDR)
- Nonproliferative Diabetic
- Retinopathy (NPDR)
Age-related Macular Degeneration (AMD)
- Dry Age-related Macular Degeneration (Dry AMD)
- Wet Age-related Macular Degeneration (wAMD)
- Neovascular Age-related Macular Degeneration (nAMD)
- Geographic Atrophy (GA)
Inherited Retinal Disease
- Stargardt Disease
- Retinitis Pigmentosa (RP)
Retinal Vein Occlusion (RVO)
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
- Hemi-Retinal Vein Occlusion (HRVO)
- Retinal Artery Occlusion (RAO)
Uveitis
- Panuveitis
- Anterior Uveitis
- Intermediate Uveitis
- Posterior Uveitis
The Polus Guarantee
Only Pay for Results.
We understand the operational and financial pressure clinics face with every trial. That’s why Polus Health operates on an outcomes-based model.
- No subscription fees
- No monthly minimums
- One-time admin startup fee
- Only billed for successful patient screenings / enrollments
It’s a simple, transparent model built on trust, results, and shared success. We only succeed when you do.
SFR Calculator
Calculate Your Savings From Your Optimized Screen-Failure Rate.
Enter your trial parameters to see how improved screen-fail performance translates into real-world savings.
Get Started.
Pick a time that works for you. We’ll discuss your current enrollment challenges, identify where inefficiencies exist, and show you where we can help.
No preparation. No commitment. Just a simple conversation.